Weigh the Risks and Benefits of DOACs for Venous Thromboembolism

March 2016

Which anticoagulant should be used to TREAT venous thromboembolism?

New Chest guidelines give preference to direct oral anticoagulants (DOACs)...such as apixaban (Eliquis) or rivaroxaban (Xarelto).

But don't assume that DOACs are the best choice for everyone.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Table of Contents

Antithrombotics Weigh the Risks and Benefits of DOACs for Venous Thromboembolism
Stroke Re-Evaluate Alteplase Contraindications in Your Stroke Protocol
Cardiology Make Sure Patients Go Home on Only One ACEI or ARB
IV Medications Discourage Stocking Sterile Water 1 L Bags Outside of the Pharmacy
Statins Don't Automatically Override Statin Interactions
Specialty Meds Watch for Insurance Flags or Rejects for Specialty Meds
Med Adherence Use Teach-Back Technique to Improve Med Adherence
New Drugs Explain New ADHD Forms Don't Offer Much Advantage Over Older Meds
Fungal Infections Consider Echinocandins First-Line for Most Candidemia
Tapering Don't Suggest Stopping Paroxetine "Cold Turkey"
Allergic Reactions Verify Allergies Before Jumping to Vancomycin